Ferdinand Haslbauer

1.9k total citations
26 papers, 292 citations indexed

About

Ferdinand Haslbauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Ferdinand Haslbauer has authored 26 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Ferdinand Haslbauer's work include Bone health and treatments (7 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Ferdinand Haslbauer is often cited by papers focused on Bone health and treatments (7 papers), Advanced Breast Cancer Therapies (6 papers) and Cancer Treatment and Pharmacology (6 papers). Ferdinand Haslbauer collaborates with scholars based in Austria, Switzerland and Sweden. Ferdinand Haslbauer's co-authors include Richard Greil, Georg Pfeiler, Daniel Egle, Michael Gnant, Florian Fitzal, Christian Marth, Christian F. Singer, Christian Fesl, Marija Balić and Viktor Wette and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ferdinand Haslbauer

24 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ferdinand Haslbauer Austria 8 211 83 79 53 51 26 292
Laia Garrigós Spain 9 322 1.5× 46 0.6× 177 2.2× 35 0.7× 41 0.8× 35 402
Stefanos Labropoulos Greece 9 201 1.0× 59 0.7× 123 1.6× 29 0.5× 22 0.4× 13 313
Edgar Braendle United States 5 160 0.8× 179 2.2× 50 0.6× 24 0.5× 21 0.4× 10 321
Carol Ward United Kingdom 8 110 0.5× 52 0.6× 32 0.4× 28 0.5× 15 0.3× 13 259
Benjamin J. Gigliotti United States 7 188 0.9× 106 1.3× 93 1.2× 28 0.5× 8 0.2× 18 392
Ivonne Vázquez Spain 11 124 0.6× 56 0.7× 21 0.3× 37 0.7× 30 0.6× 27 357
Hak Min Lee South Korea 12 212 1.0× 84 1.0× 81 1.0× 146 2.8× 13 0.3× 32 389
Nazir Jamal Canada 6 101 0.5× 92 1.1× 65 0.8× 27 0.5× 7 0.1× 9 270
V. Leonardi Italy 10 188 0.9× 34 0.4× 85 1.1× 53 1.0× 14 0.3× 33 269
Ankur Modi United States 6 273 1.3× 63 0.8× 60 0.8× 28 0.5× 98 1.9× 10 395

Countries citing papers authored by Ferdinand Haslbauer

Since Specialization
Citations

This map shows the geographic impact of Ferdinand Haslbauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferdinand Haslbauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferdinand Haslbauer more than expected).

Fields of papers citing papers by Ferdinand Haslbauer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferdinand Haslbauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferdinand Haslbauer. The network helps show where Ferdinand Haslbauer may publish in the future.

Co-authorship network of co-authors of Ferdinand Haslbauer

This figure shows the co-authorship network connecting the top 25 collaborators of Ferdinand Haslbauer. A scholar is included among the top collaborators of Ferdinand Haslbauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferdinand Haslbauer. Ferdinand Haslbauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Otremba, Burkhard, et al.. (2024). Association between serum IgG concentrations and the incidence of infections in patients with chronic lymphocytic leukemia and secondary immunodeficiency under treatment with Privigen. International Journal of Clinical Pharmacology and Therapeutics. 62(6). 241–249. 1 indexed citations
2.
Singer, Christian F., Daniel Egle, Richard Greil, et al.. (2024). Abstract PO3-16-10: Real-world outcomes with first-line ribociclib + endocrine therapy in patients with metastatic HR+, HER2– breast cancer: Fourth interim analysis of REACH AUT trial. Cancer Research. 84(9_Supplement). PO3–16. 1 indexed citations
3.
Diel, Ingo, Richard Greil, Jan Janßen, et al.. (2022). Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. Supportive Care in Cancer. 30(11). 9267–9278. 2 indexed citations
4.
Gnant, Michael, Sophie Frantal, Georg Pfeiler, et al.. (2022). Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.. Journal of Clinical Oncology. 40(16_suppl). 507–507. 11 indexed citations
5.
6.
Singer, CF, Daniel Egle, Richard Greil, et al.. (2020). 172P REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC). Annals of Oncology. 31. S77–S78. 1 indexed citations
7.
Haslbauer, Ferdinand, Andreas Petzer, Antoaneta Tomova, et al.. (2019). Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis. Supportive Care in Cancer. 28(4). 1855–1865. 5 indexed citations
8.
9.
Haslbauer, Ferdinand. (2018). Long-Term Progression-Free Survival in a Patient with Metastatic Leiomyosarcoma of the Inguinal Region Treated with Trabectedin. Case Reports in Oncology. 11(1). 246–251. 3 indexed citations
10.
Gnant, Michael, Georg Pfeiler, Guenther G. Steger, et al.. (2018). Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.. Journal of Clinical Oncology. 36(15_suppl). 500–500. 16 indexed citations
11.
Hochmair, Maximilian J., Martin Filipits, Andrea Mohn-Staudner, et al.. (2017). P3.02b-101 EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib. Journal of Thoracic Oncology. 12(1). S1254–S1254. 2 indexed citations
12.
Mądry, Radosław, Ferdinand Haslbauer, Tibor Csőszi, et al.. (2016). Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wiener klinische Wochenschrift. 128(7-8). 238–247. 9 indexed citations
13.
Steger, Guenther G., Edgar Petru, Ferdinand Haslbauer, et al.. (2016). Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study. Annals of Oncology. 27. vi74–vi74. 2 indexed citations
14.
Gnant, Michael, Georg Pfeiler, Peter Dubsky, et al.. (2015). Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.. Journal of Clinical Oncology. 33(15_suppl). 504–504. 7 indexed citations
15.
Haslbauer, Ferdinand. (2014). Case report of nab-paclitaxel in metastatic pancreatic cancer. memo - Magazine of European Medical Oncology. 7(1). 39–42.
16.
Merlini, Laura, Giacomo Cartenì, Caterina Stelitano, et al.. (2013). Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. Cancer Management and Research. 5. 205–205. 7 indexed citations
17.
Fiegl, Michael, Florian Falkner, Michael Steurer, et al.. (2011). Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Annals of Hematology. 90(9). 1083–1091. 7 indexed citations
18.
Eisterer, Wolfgang, et al.. (2010). RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy. Current Medical Research and Opinion. 27(2). 355–363. 6 indexed citations
19.
Haslbauer, Ferdinand & Michael Fiegl. (2009). Bisphosphonates as adjuvant therapy in multimodal pain management. memo - Magazine of European Medical Oncology. 2(3). 161–165. 2 indexed citations
20.
Fiegl, Michael, Georg Hopfinger, Stefan Brugger, et al.. (2006). Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia. Cancer. 107(10). 2408–2416. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laia Garrigós Breakdown of academic impact, for papers by Stefanos Labropoulos Breakdown of academic impact, for papers by Edgar Braendle Breakdown of academic impact, for papers by Carol Ward Breakdown of academic impact, for papers by Benjamin J. Gigliotti Breakdown of academic impact, for papers by Ivonne Vázquez Breakdown of academic impact, for papers by Hak Min Lee Breakdown of academic impact, for papers by Nazir Jamal Breakdown of academic impact, for papers by V. Leonardi Breakdown of academic impact, for papers by Ankur Modi
Rankless by CCL
2026